HIGHLIGHTS
- who: Feihang Wang et al. from the Qianfoshan Hospital, Shandong University, China have published the paper: Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma, in the Journal: (JOURNAL)
SUMMARY
Sorafenib is recommended as the first-line therapy, and its median overall survival (OS) was 7.13- 9.6 months for HCC patients with extrahepatic metastases. In 2018, a meta-analysis reported that the median OS of patients with pulmonary metastases from colorectal carcinoma undergoing pulmonary metastasectomy was 43 months. In China . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.